| abstract |
The present invention relates to compounds of formula (I) wherein R 1 is hydrogen, lower alkyl, halogen, lower alkyl substituted with halogen, lower alkoxy, lower alkoxy substituted with halogen, cyano, nitro, C-cycloalkyl, —CH — C-cycloalkyl, - O-CH-C-cycloalkyl, -O- (CH) -O-lower alkyl, S (O) CH, SF, -C (O) NH-lower alkyl, phenyl, -O-pyrimidinyl, optionally substituted with lower alkoxy, substituted with halogen, or is benzyl, oxetanyl or furanyl; m represents 1 or 2; Ar is aryl or heteroaryl selected from the group consisting of phenyl, naphthyl, pyrimidinyl, pyridinyl, benzothiazolyl, quinolinyl, quinazolinyl, benzo [d] [1.3] dioxolyl, 5,6,7,8-tetrahydroquinazolinyl, pyrazolyl, pyrazinyl pyridazinyl or 1,3,4-oxadiazolyl; Y represents a bond, —CH—, —CHCH—, —CH (CF) - or —CH (CH) -; R 1 is hydrogen or lower alkyl; A represents CR or N and R represents hydrogen, cyano, halogen or lower alkyl; R 'represents hydrogen or halogen; with the proviso that when R 'is halogen, then A is CH; B represents CH or N; n represents 0, 1 or 2; X is a bond, —CH— or —O—; or their pharmaceutical active acid addition salts. The compounds of formula I have been found to have good affinity for receptors associated with trace amines (TAARs), especially TAAR1. The compounds can be used to treat depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder (ADHD), stress disorders, psychotic disorders such as schizophrenia, neurological diseases such as Parkinson's disease, neurodegenerative disorders such |